Ratings P3 Health Partners Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
0.54 ^USD	-8.47%		+1.48%	-61.70%

May. 22	P3 Health Partners Inc. announced that it expects to receive $42.2598 million in funding from Chicago Pacific Founders	CI
May. 08	Earnings Flash (PIII) P3 HEALTH PARTNERS Reports Q1 Revenue $388.5M, vs. Street Est of $357.2M	MT

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
The company shows low valuation levels, with an enterprise value at 0.09 times its sales.
The company appears to be poorly valued given its net asset value.
The company has a low valuation given the cash flows generated by its activity.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
P3 HEALTH PARTNERS INC.	-61.70%	70.58M	-
MODERNA, INC.	+54.05%	63.85B	B-
IQVIA HOLDINGS INC.	-2.02%	41.83B	B
LONZA GROUP AG	+40.01%	40.47B	A
CELLTRION, INC.	-10.22%	27.17B	C
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B	B
BIO-TECHNE CORPORATION	+2.89%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.49%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality